Autopsy report · NCT05810961

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Sponsor decision”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 month after it had already started.
Ran for about 1 year 6 months before it stopped.
8 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: argenx
Sponsor type: Industry
Conditions: Membranous Nephropathy
Interventions: efgartigimod IV; placebo
Participants: 8
Sites: 31
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.